The Canadian Optimal Therapy of COPD Trial: Design, Organization and Patient Recruitment | Zendy

Shawn D. Aaron | Zendy; Katherine L. Vandemheen | Zendy; Dean Fergusson | Zendy; Mark Fitzgerald | Zendy; François Maltais | Zendy; Jean Bourbeau | Zendy; Roger Goldstein | Zendy; Andrew McIvor | Zendy; Meyer Balter | Zendy; Denis E. O’Donnell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Canadian Optimal Therapy of COPD Trial: Design, Organization and Patient Recruitment

Author(s) -

Shawn D. Aaron,

Katherine L. Vandemheen,

Dean Fergusson,

Mark Fitzgerald,

François Maltais,

Jean Bourbeau,

Roger Goldstein,

Andrew McIvor,

Meyer Balter,

Denis E. O’Donnell

Publication year - 2004

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2004/394710

Subject(s) - medicine , salmeterol , copd , exacerbation , placebo , randomized controlled trial , bronchodilator , randomization , quality of life (healthcare) , clinical trial , physical therapy , salbutamol , tiotropium bromide , inhaler , intensive care medicine , fluticasone propionate , asthma , lung function , lung , alternative medicine , nursing , pathology

There are no published studies that have assessed whether adding long-acting beta 2-agonist bronchodilators and/or inhaled steroids to chronic therapy with tiotropium would provide additional clinical benefit to patients with moderate to severe chronic obstructive pulmonary disease (COPD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research